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RESUMO
O principal objectivo do estágio na Eurotrials foi complementar os
conhecimentos adquiridos durante a Licenciatura em Ciências Biomédicas e no
Mestrado em Biomedicina Farmacêutica.
O estágio na Eurotrials pretendeu preparar o estagiário para trabalhar como
Monitor de Ensaios Clínicos. Incluiu também uma visão geral sobre a forma de
trabalhar e actividades desenvolvidas nos diferentes departamentos da empresa.
Todo o conhecimento previamente adquirido na Universidade foi complementado
durante o estágio.
Este estágio de 9 meses como Monitora em treino foi uma excelente preparação
para trabalhar na área dos Ensaios Clínicos e para isso contribuiu também a
experiência transdisciplinar.
Continuar como colaboradora da Eurotrials irá proporcionar a oportunidade de
realizar outras actividades que até ao momento não foram possíveis,
consolidando os conhecimentos já adquiridos, permitindo o desenvolvimento de
mais competências e maior autonomia.
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ABSTRACT
The primary objective of the training in Eurotrials was to complement the
knowledge acquired during the Degree in Biomedical Sciences and during the
Master in Pharmaceutical Biomedicine.
Eurotrials training program aimed to prepare the trainee to work as a CRA. It also
included an overview of Company departments namely the working activities
performed.
All knowledge previously acquired in the University was complemented during
the training.
This 9-month experience as a CRA trainee was an excellent preparation to work
in Clinical Trials and the transdisciplinar experience greatly contributed to this
preparation.
Continuing as a collaborator at Eurotrials will give the CRA trainee the
opportunity to perform other activities not yet experienced, to consolidate know-
how and to get more experience as well as to become more autonomous.
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SINOPSE
Título do
Estágio: Monitora de Ensaios Clínicos - uma experiência de 9 meses
Objectivos:
O principal objectivo do estágio na Eurotrials foi complementar os
conhecimentos adquiridos durante a Licenciatura em Ciências
Biomédicas e o Mestrado em Biomedicina Farmacêutica.
O estágio na Eurotrials pretendeu preparar o estagiário para
trabalhar como Monitor de Ensaios Clínicos. Também incluiu uma
visão geral sobre a forma de trabalhar e actividades desenvolvidas
nos diferentes departamentos da empresa.
Duração do
Estágio: 9 meses
Período do
Estágio:
06 de Setembro de 2010 (data de início do estágio)
06 de Junho de 2011 (data de conclusão do estágio)
Desenho do
Estágio:
Coordenação:
Luís Almeida (Director do Mestrado em Biomedicina Farmacêutica)
António Amaro (Orientador/Professor Coordenador da
Universidade de Aveiro)
Susana Bule (Co-orientadora/Directora Executiva da Eurotrials)
Raquel Reis (Responsável pelo Departamento de Ensaios Clínicos
da Eurotrials)
Graça Silveira (Gestora de Projecto)
Isabel Pinto (Gestora Operacional de Monitores)
Relatório de
Estágio escrito
por:
Maria Inês Cabral
Conclusões:
Todo o conhecimento previamente adquirido na Universidade foi
complementado durante o estágio.
Este estágio de 9 meses como Monitora em treino foi uma
excelente preparação para trabalhar na área dos Ensaios Clínicos
e para isso contribuiu também a experiência transdisciplinar.
Continuar como colaboradora da Eurotrials irá proporcionar a
oportunidade de realizar outras actividades que até ao momento
não foram possíveis, consolidando os conhecimentos já
adquiridos, permitindo o desenvolvimento de mais competências e
maior autonomia.
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SYNOPSIS
Training Title: Clinical Research Associate (CRA) – a 9 month experience
Objectives:
The primary objective of the training in Eurotrials was to
complement the knowledge acquired during the Degree in
Biomedical Sciences and during the Master in Pharmaceutical
Biomedicine.
Eurotrials training program aimed to prepare the trainee to work as
a CRA. It also included an overview of Company departments
namely the working activities performed.
Training
Duration: 9 months
Training period: 6
th September 2010 (training initiation date)
6th June 2011 (Training completion date)
Training
Design:
Coordination:
Luís Almeida (Pharmaceutical Biomedicine Master Director)
António Amaro (Supervisor/ Coordinator Professor of University of
Aveiro)
Susana Bule (Co-supervisor/Executive Director of Eurotrials)
Raquel Reis (Eurotrials Head of Clinical Trials Department)
Graça Silveira (Project Manager)
Isabel Pinto (Line Manager)
Training Report
performed by: Maria Inês Cabral
Conclusions:
All knowledge previously acquired in the University was
complemented during the training.
This 9-month experience as a CRA trainee was an excellent
preparation to work in Clinical Trials and the transdisciplinar
experience greatly contributed to this preparation.
Continuing as a collaborator at Eurotrials will give the CRA trainee
the opportunity to perform other activities not yet experienced, to
consolidate know-how and to get more experience as well as to
become more autonomous.
University of Aveiro | Autonomous Section of Health Sciences
Year 2010/2011
TrainingReport_IC_39215_05Jul2011.pdf Page 7 of 68
TABLE OF CONTENTS
JUDGES.................................................................................................................................................. 1
ACKNOWLEDGMENTS ......................................................................................................................... 2
SINOPSE................................................................................................................................................. 3
SYNOPSIS .............................................................................................................................................. 6
TABLE OF CONTENTS.......................................................................................................................... 7
LIST OF FIGURES.................................................................................................................................. 8
LIST OF TABLES ................................................................................................................................... 8
1. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS .......................................................... 9
2. INTRODUCTION............................................................................................................................ 11
2.1. TRAINING OBJECTIVES ........................................................................................................11
2.2. STATE OF THE ART...............................................................................................................11
3. VISION ABOUT THE INSTITUTION – EUROTRIALS.................................................................. 18
4. TRANSDICIPLINAR EXPERIENCE.............................................................................................. 21
4.1. DATA MANAGEMENT.............................................................................................................21
4.2. BIOSTATISTICS......................................................................................................................28
5. MONODISCIPLINAR EXPERIENCE............................................................................................. 32
5.1. CLINICAL TRIALS MONITORING...........................................................................................32
5.2. DEVELOPED ACTIVITIES ......................................................................................................34
5.2.1. Confidentiality ............................................................................................................................... 34
5.2.2. Training......................................................................................................................................... 34
5.2.3. Characterization of the Clinical Trials............................................................................................ 35
5.2.4. Archive and Documentation Management .................................................................................... 39
5.2.5. Feasibility ...................................................................................................................................... 40
5.2.6. Qualification .................................................................................................................................. 42
5.2.7. Clinical Trials Application to National Authorities .......................................................................... 42
5.2.8. Investigator Meetings.................................................................................................................... 45
5.2.9. CRA Training Meetings................................................................................................................. 46
5.2.10. Initiation......................................................................................................................................... 47
5.2.11. Notification of inclusion of the first patient to Competent Authorities............................................. 48
5.2.12. Monitoring ..................................................................................................................................... 48
5.2.13. Elaboration of a Progress Report.................................................................................................. 51
5.2.14. Close-out/Termination................................................................................................................... 51
5.2.15. Development of a Clinical Study Report ....................................................................................... 53
5.2.16. Project Hand-over ......................................................................................................................... 54
5.2.17. Audits............................................................................................................................................ 54
6. DISCUSSION AND CONCLUSION............................................................................................... 56
7. REFERENCES............................................................................................................................... 59
8. APPENDICES................................................................................................................................ 60
8.1. APPENDIX A ...........................................................................................................................60
University of Aveiro | Autonomous Section of Health Sciences
Year 2010/2011
TrainingReport_IC_39215_05Jul2011.pdf Page 8 of 68
8.2. APPENDIX B ...........................................................................................................................64
8.3. APPENDIX C ...........................................................................................................................67
LIST OF FIGURES
Figure 1 - From drug synthesis to approval. .....................................................................................16
Figure 2 - R&D Eurotrials activities. ..................................................................................................19
Figure 3 - Eurotrials organogram. .....................................................................................................20
Figure 4 - Data Management Department Organogram...................................................................22
Figure 5 - Data Management workflow. ............................................................................................23
Figure 6 - Biostatistics Department Organogram. ............................................................................28
Figure 7 - Interactions between Biostatistics and other Eurotrials departments. .............................31
Figure 8 - Clinical Trials Department Organogram. ..........................................................................32
Figure 9 - Distribution of clinical trials performed by Eurotrials (data between 1996 and December
2010), according to the therapeutic area. .........................................................................................33
Figure 10 - Distribution of clinical trials performed by Eurotrials (data between 1996 and
December 2010), according to the study phase. ..............................................................................33
Figure 11 - Distribution of Clinical Trials where CRA trainee was involved according to study
phase.................................................................................................................................................37
Figure 12 - Clinical Trials Life Cycle. ................................................................................................38
Figure 13 - Overview of developed activities within Clinical Trials Life Cycle stages.......................39
Figure 14 - Approval timelines of a Clinical Trial Application............................................................43
LIST OF TABLES
Table 1 - Activities developed by Data Management and Biostatistics Departments. .....................21
Table 2 - Notations attributed according to the missing data. ..........................................................25
Table 3 - Characterization of the Clinical Trials where CRA trainee was involved...........................36
Table 4 - Details of Global Distribution of Clinical Trials where CRA trainee was involved. ............36
University of Aveiro | Autonomous Section of Health Sciences
Year 2010/2011
TrainingReport_IC_39215_05Jul2011.pdf Page 9 of 68
1. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
Abbreviation or Term Definition/Explanation
CA Competent Authority
CEIC Ethics Committee for Clinical Research
CNPD Portuguese Data Protection Authority
COTEC Business Association for Innovation
CRA Clinical Research Associate
CSA Clinical Study Agreement
CT Clinical Trial
CTA Clinical Trial Assistant
CTMS Clinical Trial Management System
CRF Case Report Form
CRO Clinical Research Organization
DDD Data Definition Documentation
DMD Data Management Department
DMP Data Management Plan
DMQC Data Management Quality Controller
DQCR Database Quality Control Report
DSD Database Support Documentation
DVP Data Validation Plan
EC Ethics Committee
EMA European Medicines Agency
FDA Food and Drug Administration
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FQ Feasibility Questionnaire
FSA Feasibility Study Assessment
IAPMEI Institute for the Support of Small and Medium-sizedEnterprises
ICF Informed Consent Form
IF Investigator File
IM Investigator Meeting
IMP Investigation Medicinal Product
INFARMED National Authority of Medicines and Health Products,IP
IP Public Institute
ITS Information Technology Specialist
IVRS Interactive Voice Response System
ORL Otorhinolaryngology
PI Principal Investigator
PhF Pharmacy File
R&D Research and Development
SAP Statistical Analysis Plan
SAS Statistical Analysis Data Set
SDV Source Data Verification
SIV Site Initiation Visit
SME Small and Medium-sized Enterprise
TMF Trial Master File
UKAS United Kingdom Accreditation Service
WHO World Health Organization
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2. INTRODUCTION
2.1.TRAINING OBJECTIVES
The main objective of this 9-month training was to prepare the trainee in the best
working practices to work as a Clinical Research Associate (CRA) and to
consolidate the knowledge acquired in the Degree and Master through practical
experience.
Moreover, considering the Company organization, additional objective was to be
able to interact with other areas of expertise, namely Data Management and
Biostatistics, in order to gather know-how related with information flow and
processes that are also crucial for the CRA performance.
2.2.STATE OF THE ART
According to the Office of Technology Assessment(1), Pharmaceutical Research
and Development (R&D) is the process of discovering, developing and bringing
to market new drug products. This process is influenced by science and
economy, while the first one defines opportunities and constrains, the second
one decides which opportunities and scientific experiments will be target of
industrial research. Investors determine if they will invest in a research project
according to investment’s costs and risks.
Drug discovering processes have changed over the years. At the beginning of
medicines history, products came from nature. The method “try and error” was
used, the reason behind those effects was not known and anyone could try the
drug.
“Physicians pour drugs of which they know little, to cure diseases of which they
know less, into humans of which they know nothing” by Voltaire, c. 1760.
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With the evolution of medicine, new approaches appeared and nowadays, the
process of drug discovery and development is strictly regulated and several steps
are needed for drugs to become available to anyone.
In the 1990s, genetic engineering, computer modelling and biotechnology had a
great impact in R&D processes. Computer modelling became essential due to its
capability of predicting how a molecule will work in human body. It allows virtual
manipulation of a molecule in order to enhance its activity and understands the
relation drug-receptor. This will reduce costs of synthesizing molecules that will
not pass in future tests. This advantage is only possible due to the great
improvement of diseases mechanisms knowledge.
When drug synthesis phase starts, the major objective is to select the best route
of administration of substances and know how they react in different conditions
and with different reagents. Stability, pH, solubility, biocompatibility with organic
solvents are examples of characteristics that needed to be identified in order to
predict drug absorption and distribution in vivo and for studies of structure–
activity relationship, which may direct future synthesis(2).
This in vitro step of R&D process includes a huge number of tests and results in
some compounds that are considered to have potential as a new medicine. The
next step is the in vivo testing, which includes preclinical and clinical trials.
According to Griffin(3), during the R&D process of a potential new pharmaceutical
compound, proving quality, efficacy and safety of the potential new drug are the
primary objectives. In what concerns safety, compound risks must be inferior to
benefits. Preclinical trials are important to predict the range of safe exposures to
the drug and to identify the risks involved in the overdose of this safety range.
Preclinical trials importance has increased after Thalidomide event. Nowadays
there is legislation requiring several preclinical tests before a drug is administered
into humans. These tests include(4):
 Biochemical-pharmacological studies (analysis of drug binding to
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receptors, understanding the kinetics of interaction and the characteristics
of the binding site itself).
 Pharmacokinetics studies (in order to obtain information regarding
absorption, distribution, metabolism and elimination of the drug).
 Toxicological investigations to evaluate the potential for:
o Toxicity associated with acute or chronic administration
o Genetic damage (genotoxicity, mutagenicity)
o Production of tumors (oncogenicity or carcinogenicity)
o Causation of birth defects (teratogenicity).
Preclinical trials induce a great reduction of the number of drugs with potential to
be used in humans due to all required specificities that substances must meet in
order to be administered in man. After the minimum required information is
obtained, clinical trials can begin.
According to the World Health Organization (WHO), “a clinical trial is any
research study that prospectively assigns human participants or groups of
humans to one or more health-related interventions to evaluate the effects on
health outcomes. Interventions include but are not restricted to drugs, cells and
other biological products, surgical procedures, radiological procedures, devices,
behavioural treatments, process-of-care changes, preventive care, etc”(5).
Typically, clinical trials can be grouped in 4 phases(6, 7):
 Phase I – Human Pharmacology
o “First in man studies”
o 20-80 subjects that are usually healthy volunteers but occasionally may
be patients with the targeted disease.
o Help determine how the human body will handle the drug
(pharmacokinetics), how the drug will behave within the human body
(pharmacodynamics) and what doses to use for Phase II clinical
studies (e.g., side effects associated with increasing doses).
 Phase II – Therapeutic Exploratory
o Use patients (usually several hundred) with the disease or condition
University of Aveiro | Autonomous Section of Health Sciences
Year 2010/2011
TrainingReport_IC_39215_05Jul2011.pdf Page 14 of 68
that the drug is intended to treat.
o Typically well controlled, generate early data on the drug’s efficacy
and safety while being used to treating the particular disease.
 Phase III – Therapeutic Confirmatory
o Called pivotal trials: the trial will determine whether a new drug is
inferior, equivalent, or superior to the standard treatment.
o Usually consisting of hundreds to thousands of patients.
o Aim to prove a drug’s effectiveness and safety (positive benefit/risk
balance).
o Help predict how the drug may behave in the general population
and establish the information that will appear on the drug label.
 Phase IV – Therapeutic Use
o Drug is already approved and marketed.
o Can provide more information on the drug’s effectiveness and
safety in real-life conditions and either confirm or add indications to
a drug’s label.
o Refine understanding of benefit/risk relationship in general or
special populations and/or environments.
As described in ICH guideline E8, studies do not have to respect a temporal
order, study objectives are more important, “new data may suggest the need for
additional studies that are typically part of an earlier phase”(6).
After obtaining all required information about the drug and before starting phase
IV clinical trials, a market authorization application can already be submitted.
Every country has a national authority responsible for the evaluation of drugs and
their submission applications. In Portugal, the national authority is INFARMED
(National Authority of Medicines and Health Products, IP) being also the local
representation of the European Medicines Agency (EMA) while in the United
States of America is the Food and Drug Administration (FDA) and in Canada is
the Health Protection Branch Drugs Directorate. In the European Union there are
4 different procedures to obtain a market authorization(8, 9):
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 Centralized – the authorization is valid in all European Union member
states. The application is evaluated by EMA, which has a group
responsible for the scientific evaluation of the application (Committee for
Medicinal Products for Human Use). The European Commission reviews
the evaluation and adopts a decision.
 Decentralized – only possible when the product has no previous market
authorization in any member state. The submission occurs simultaneously
in various member states but one will be responsible for the elaboration of
an assessment report (reference member state). Based on this report and
comments made by member states, the authorization will be obtained or
not.
 Mutual recognition – when a market authorization for a product has been
obtained in a member state and other member states can approve or not
the decision made by the first member state, recognizing its decision.
 National – The competent authorities of the Member States are
responsible for granting marketing authorizations for medicinal products,
which are placed on their markets.
When the market approval is obtained, the real test of the drug starts since
anyone can take the product and for most cases there are no studies for the real
environment where the drug will be administrated. This is the major limitation of
clinical trials due to the close monitoring existence and to the restricted inclusion
and exclusion criteria that studies patients must have to participate in the trial.
Figure 1 represents a scheme where the process of drug development is
described, beginning with compounds synthesis to drug approval and
introduction in the market(4). It gives a clear idea on the number of potential
compounds that will be screened during this process, ending with the best
compound among 10000 substances that started the preclinical testing phase.
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Figure 1 - From drug synthesis to approval.
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Ethical issues regarding human safety during the history of medicine and
pharmaceutical industry created the increased need of control and regulate R&D
all the processes with special attention to animal and human protection issues.
The Nuremberg Code, Helsinki Declaration, ICH guidelines, local, European and
FDA legislations are the main reference for the standard procedures in clinical
research.
In Portugal, INFARMED, Ethics Committee for Clinical Research (CEIC) and the
Portuguese Data Protection Authority (CNPD) are responsible for the evaluation
and approval of a clinical trial. INFARMED is responsible not only for the
approval of clinical trials but also for all other issues related with medicines and
their use in the national territory.
National Legislation includes local requirements and the transposition of several
European directives. Some of the more important Portuguese requirements in
medicines for human use are described in the Decree-law no. 176/2006 of
August 30 (known as the Medicinal Product Statute), in the Law no. 46/2004 of
August 19 (known as the Clinical Trials Law) and in Decree-law no. 102/2007 of
April 2 (known as GCP Directive).
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3. VISION ABOUT THE INSTITUTION – EUROTRIALS
Established in Lisbon in 1995, Eurotrials, Scientific Consultants, is a private
owned company specialized in clinical research and scientific consultancy in the
Health area.
Currently, the company has it Head Quarters in Portugal, one office in Brazil, a
local representation in Chile and Argentina. Eurotrials is also present through
partners in other countries of Europe, and has some collaborations in
Portuguese-speaking African countries. This success “stands on pillars that have
marked its personality since it was founded: creativity in finding solutions, unique
technology, multidisciplinary expertise, solid experience and quality. It is qualified
to participate in each and every step clinical, translational or epidemiological
research project, from start of the research until the Final results are
available”(10).
In Portugal, Eurotrials is recognized and certified by different entities(11):
 ISO - certified by ISO 9001 since 2001 throw Lloyd’s Register Quality
Assurance with United Kingdom Accreditation Service (UKAS). After that,
in 2002 and 2008 it was obtained the certification to ISO 9001:2000 and
ISO 9001:2008, respectively.
 “Rede PME Inovação COTEC” – since 2007, Eurotrials belongs to this
group of Small and Medium-sized Enterprises (SMEs) recognized by their
innovative attitude and activities, which make them an example of creation
of value for the country.
 Leading SME – the Institute for the Support of Small and Medium-sized
Enterprises (IAPMEI) considered Eurotrials in 2007 as a leading SME due
to their quality of performance and risk profile.
Nowadays, Eurotrials aims to achieve the following objectives(12):
 Continue to develop innovative Clinical Research projects.
 Bridge the gap between Basic, Academic Research and market –
Translational research.
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 Interact with Institutional Research Groups for the potential development
of therapeutic alternatives, medical devices and other innovative
approaches.
 Promote the development of a network of centres of excellence.
In Portugal, the company performs several activities during R&D process, which
are represented in Figure 2(12).
Figure 2 - R&D Eurotrials activities.
In order to be able to perform its services and activities, Eurotrials is organized in
the following departments, which communicate and interact with each other on a
daily basis (Figure 3(13)):
 Research and Development
 Clinical Trials
 Epidemiology & Late Phase Research
 Data Management
 Biostatistics
 Regulatory Strategy & Affairs
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 Pharmacovigilance
 Pharmacoeconomics
 Quality
 Teaching and Training
Figure 3 - Eurotrials organogram.
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4. TRANSDICIPLINAR EXPERIENCE
The training program developed at Eurotrials involved close interaction with two
departments within the company: Data Management and Biostatistics. These
departments have different roles, which are explained in sections 4.1 and 4.2,
respectively.
A summary of the developed activities by Data Management and Biostatistics
departments are presented in Table 1.
Table 1 – Activities developed by Data Management and Biostatistics Departments.
Data Management Biostatistics
 Clinical Data Management System
 Database Development
 Data Entry (remote or in-house)
 Data Verification
 On-going Data Management
 Clean Database
 Database Quality Control
 Database Reports
 Study Protocol Support
 Statistical Analysis Plan
 Statistical Analysis
 Statistical Report
 General Consultancy
 Support on Medical Writing
4.1.DATA MANAGEMENT
The Data Management Department (DMD) has an important role in the transfer
of information recorded within the Case Report Form (CRF) into clean and
validated data that will be consequently analysed by Biostatistics.
A training meeting was organized to explain how the department was structured,
which, when and how activities were developed. It allowed trainee to understand
how relevant and interesting these activities are in a clinical trial and mainly, what
Data management process is.
Within this department range of activities, there are specialists from different
areas of expertise namely, Information Technology Specialists (ITS), Database
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Operators, Data Managers and Medical Reviewers. It is possible to understand
all activities developed by DMD through Figure 4(13). This figure explains Internal
Department organization that is aligned with the circuit of data since its inclusion
in the system, by a Data-Entry Operator until the evaluation by a Data
Management Quality Controller (DMQC).
Figure 4 - Data Management Department Organogram.
The relation of this team with a clinical trial/epidemiological study involves in
many instances the design and development of CRFs, either on paper or
electronic format. In all most cases, when this department is contracted to
manage the data, they are also responsible for the development of the CRF. For
this activity to be duly accomplished, it is important to know and understand the
study protocol and main variables in order to be able to introduce all necessary
fields within the CRF and not needless ones.
Within a specific clinical study, the workflow since the design of the CRF until the
sending of cleaned data to Biostatistics Department/team includes several steps
which are explained bellow and summarized in the Figure 5.
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Figure 5 - Data Management workflow.
1. Definition of activities timelines
Before the CRF development begins, it is essential to define the activities to be
performed as well as the timelines for each activity in order to ensure the delivery
of the product to the client within the pre-defined timelines and according to
agreed specifications.
2. Data Management Plan
Data Management Plan (DMP) defines all the issues that will be important and
helpful on the handling of data. It must include, at least, internal management
rules, study team and how the DM study team will create and organize their Trial
Master File (TMF).
3. Annotated CRF Development
The Annotated CRF is an important document used by all team members and
describes all variables/fields within the CRF. It maps each item on the CRF to the
corresponding variables in the database.
4. Data Definition Documentation
The Data Definition Documentation (DDD) is an especially useful document for
data integration in other database(s), as safety databases.
The DDD is a technical document that specifies all database tables/modules
(datasets), its fields and the code lists used for database development.
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Therefore, all database fields are described according to its attributes: type
(numeric or alphanumeric), description (label), size and code list association.
5. Database Support Documentation
The Database Support Documentation (DSD) includes the Annotated CRF and
the Data-entry Manual. The DSD states the pre-defined rules and procedures
that must be followed during data transfer to database.
This document is essential not only for data-entry procedures but also to Data
management and statistics activities (namely the Annotated CRF).
6. Database Development
For any given study, a specific database needs be developed. This database
must have into consideration the CRF structure. Therefore, all data entry screens
will be developed in order to emulate the CRF pages and datasets will be
assembled according to the pre-established requirements stated in the DDD.
7. Database Testing and Approval
Database testing is performed preferentially with real data. The objective of this
activity is to find the major number of errors/inconsistencies among the CRF
fields to prevent them from occurring when the CRF is in use and data is entered.
From these tests, a Functionality Report is written describing all detected
findings.
The Data Manager is the person responsible for correction/solving all reported
findings. Then, in order to guarantee that findings were identified and duly
corrected, a form must be signed by Data Manager and DMQC (who performed
these tests) and filled.
8. Audit Trail
Audit trail is an electronic record that tracks the data life-cycle in database. It
reports who has introduced/changed the data, when it occurred, what was
updated (old value/new value) and the reason for changing/correcting the data.
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This electronic record is validated according to FDA 21 CFR part 11 rule of the
Code of Federal Regulations. This document defines “the criteria under which the
agency considers electronic records, electronic signatures, and handwritten
signatures executed to electronic records to be trustworthy, reliable, and
generally equivalent to paper records and handwritten signatures executed on
paper”(14), i.e., if the requirements are met, the electronic records can be used in
lieu of paper records.
9. Data Transfer to Database
After Database approval and before any data-entry activity, training must be
given to Data-entry staff on the use of the Database and related documents.
The data transfer to database will be performed according to specific rules pre-
defined in the DSD. These specific rules include the handling of missing data (not
done, not known, not applicable and not available) where a specific notation is
attributed according to the type of missing data.
Table 2 – Notations attributed according to the missing data.
Type of Missing Data
Correspondent Notation for:
Alphanumeric Fields Numeric Fields
Not Done N/D -1
Not Known N/K -2
Not Available N/AV -3
Not Applicable N/A -4
10. Data Validation Plan
Data Validation Plan (DVP) is a document that lists all checks needed to be
performed in order to detect discrepancies in study data. It also describes the
type of validation that each field needs: automatic or manual. Typically, about
90% of all fields represent data that is automatically verified and only 10% needs
manual analysis. The Study Protocol, CRF and laboratory normal ranges are
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essential for the DVP development. It is prepared by a Data Manager outside the
study and approved by the study Data Manager.
DVP is used in data cleaning and validation. Although this process requires a
multidisciplinary team involvement in order to assure cross-checks accuracy, the
Study Data Manager is the final responsible for data validation.
11. Data Cleaning and Validation
According to the data entry type (double or simple), there are different stages of
data cleaning. Double entry means that there are two persons introducing the
same information in the system in order to reduce the probability of transcription
errors while simple entry means that there is only one person introducing the
information in the system.
The data cleaning and validation stages are: data entering, data cleaning (is only
done in case of double entry and the objective is to obtain a simple entry through
the confirmation that the data entered by the two persons is the same), data
validation, and issue of queries. The objective of queries can be: to confirm,
clarify or complete information.
The final objective is to obtain correct and complete data and, if necessary, the
steps can be repeated until questions are solved. After this, all deviations to the
protocol are listed and classified as Major or Minor by Sponsor or Data
Management Team and data to be eliminated is identified in the end of this
phase.
12. Database Quality Control
Before the database lock, it is important to classify errors in three categories
according to the influence in study results:
 A - when the error does not change the meaning of data
 B - when the error changes the meaning of data
 C - when the error changes the meaning of data related to study objectives
(errors from type C should not exist, however if these occur they should be
corrected).
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Study Data Manager and DMQC write a Database Quality Control Report
(DQCR) describing all errors found between study data and the database. Any
deviations identified are classified in quantity and quality (A, B or C).
13. Database Close-out Meeting
This meeting is performed in order to review deviations classification and to
confirm that the database is ready to be closed. In this meeting all the team
members should be present, as well as a statistician and a sponsor
representative.
14. Database Close-out
Authorisation from Sponsor is needed to close the database. After its closure, if
an error/problem occurs and is necessary to re-open the database, authorisation
from Sponsor is required. Besides special cases, this situation should be avoided
as this is the final step before clean data release to Biostatistics or Client.
15. Randomization Codes break
The codes can only be opened after database close and this must always be
recorded in a specific form. The codes are introduced in a program named
Statistical Analysis data Set (SAS) and a table is developed with information
regarding treatment groups and medication administrated in each group.
16. Data sending to Biostatistics
The last responsibility of the Data Management Team is to deliver all cleaned
data obtained to Biostatistics Department. After this, some clarifications may be
needed and they must always be available to help biostatisticians.
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4.2.BIOSTATISTICS
Biostatistics Department is constituted by some statisticians with different level of
knowledge and experience and also by a Senior Consultant (Figure 6(13)).
Figure 6 - Biostatistics Department Organogram.
Through a training meeting, activities performed by this Department as well as its
organization were explained to the trainee. It allowed the CRA trainee to
understand the importance and clear impact that Biostatistics have on other
Eurotrials departments’ activities (schematized in Figure 7), namely in the
following areas:
Clinical Trials
The preparation of protocol methodology sections, Statistical Analysis Plans
(SAPs), statistical reports and randomization lists/codes are the main areas of
involvement of this department in the Clinical Trials.
Epidemiology & Late Phase Research
In what concerns this department, Biostatistics prepares the methodology section
of protocols, statistical reports (usually just objectives, methodology and results)
and databases.
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Data Management
The relation between these two departments includes the sending of cleaned
data in different formats (Access, SAS or Excel) from Data Management to
Biostatistics in order to allow the statistical analysis of the information obtained
during clinical trials and epidemiologic studies.
Pharmacoeconomics
The role of Biostatistics in the Pharmacoeconomics department includes the
search of bibliography information, revision/elaboration of electronic models that
will be needed to analyse collected data, preparation of questionnaires, help in
the conduction of Expert Panels, analysis, treatment of data and finally,
elaboration of a report.
There are three Expert Panel methodologies(15):
 Delbecq – a face-to-face meeting is organized with all selected experts, in
order to discuss the questionnaire topics. A member of Eurotrials orients
the meeting and the final objective is to achieve a consensus about the
topics for the questionnaires.
 Delphi – each expert panel member receive a post questionnaire. After
receiving the answered questionnaires, Eurotrials prepares a consensus
questionnaire after statistical data analysis of data. The new questionnaire
is then sent again to experts in order to approve the conclusions. It may be
necessary to perform this circuit several times until a consensus is
obtained.
 Key-informers – a personal interview with each expert panel member
(Key-informer) is performed in order to know their opinion in a particular
subject. After all interviews, Eurotrials analyses the data, obtaining
estimates that are used to build a consensus questionnaire. This is then
sent to experts in order to approve the conclusions. As in the Delphi
method, the questionnaire may need to be changed and consequently
revised, several times.
University of Aveiro | Autonomous Section of Health Sciences
Year 2010/2011
TrainingReport_IC_39215_05Jul2011.pdf Page 30 of 68
The Sponsor should choose which methodology wants to use. Eurotrials usually
advises to use the Delbecq method due to the greater robustness of estimates
obtained through a face-to-face meeting.
Teaching and Training
Universities, private organizations and even doctors, usually contract Eurotrials,
to provide training in different areas, including statistics. In this area, there are
courses focused on practice of statistics (basics and more specific approaches),
interpretation of results and also on how to perform clinical trials sample
calculation.
Regulatory Strategy & Affairs
One of the Regulatory Strategy & Affairs department roles is to evaluate the
readability of Patient Information Leaflets. Biostatistics, in this activity, helps to
prepare the questionnaire used to evaluate if the information in the leaflet is
adequate and in the end analyses if the results are favourable.
Medical Writing
The elaboration of articles, posters, power point presentations, and others, also
needs the help from this department in sections like methodology, results and
conclusions.
Other activity performed by this department is the elaboration of trimestral
Newsletters (“Boletins Informativos”) regarding different therapeutic issues and in
which is done an evaluation of the worldwide situation of the disease, for
example.
In order to better understand how this publication is developed, it was asked to
the CRA to help prepare the document. CRA involvement included the
bibliography research and the initial written of the newsletter. It was understood
that this is a very challenging activity due to lack of credible available information
and to the difficulty of finding information for all countries in the world.
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Figure 7 - Interactions between Biostatistics and other Eurotrials departments.
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5. MONODISCIPLINAR EXPERIENCE
5.1.CLINICAL TRIALS MONITORING
Eurotrials Clinical Trials department was the first department to be created and is
the biggest department of the Company. Its organization is complex and due to
the contact with different clients/sponsors, people of this team have the
opportunity of acquire knowledge in several work environments according to:
clinical trial therapeutic area and phase, client/sponsors rules/procedures and
training structure.
In Figure 8(13) is represented the department organogram in which is possible to
observe that the global team is divided into groups leaded by Line Managers. In
each group, there are CRAs with different levels of knowledge and at the base
there are Clinical Trial Assistants (CTAs) that give administrative support to
CRAs. The organogram also represents the possible career progression within
the CRA role.
The Start-Up Team is responsible for the clinical trial application to the several
national authorities as well as for the preparation and negotiation of clinical study
agreements/study contracts with Principal Investigators (PIs), sites and sponsors.
Figure 8 - Clinical Trials Department Organogram.
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Since 1996, this department has been involved in a large number of clinical trials,
being Cardiology and Oncology the therapeutic areas with more studies. This
historical data is consistent with the status of the art where these areas
represented the major health problems for which Pharmaceutical Companies
invested more along the years. Nowadays, main trials are focused on Oncology
and Neurology (Figure 9(12)).
Figure 9 - Distribution of clinical trials performed by Eurotrials (data between 1996 and December
2010), according to the therapeutic area.
In what concerns the phases of clinical trials conducted at Eurotrials, Figure 10(12)
allows to conclude that phase III is the most common type of studies (69%) while
phases I represents the lower percentage (1%).
Figure 10 - Distribution of clinical trials performed by Eurotrials (data between 1996 and
December 2010), according to the study phase.
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5.2.DEVELOPED ACTIVITIES
During the 9-month experience as a CRA trainee in Eurotrials clinical trials
department, it was possible to work in several clinical trials as well as learning
with the different working methodologies of the different CRAs and Sponsors.
5.2.1. Confidentiality
Pharmaceutical Industry is a very competitive business area and significant
expenditure is made every year in R&D processes. In order to ensure appropriate
disclosure of confidential information, every collaborator has to sign a
Confidentiality Agreement before starting its functions in the company. This
agreement has an enhanced importance in Clinical Research Organizations
(CROs) due to their several different clients, which increases the probability of
dealing with confidential, sometimes competitive, information.
In this area of activity, Confidentiality is a mind-set of good practices and a “way
of living” that is evidenced through the signature of the Confidentiality Agreement.
This is the first action of any collaborator joining Eurotrials and as CRA trainee
this document was signed before starting the activities in Eurotrials.
This signed agreement created restrictions on the information to be included by
the CRA trainee in the Training Report, namely clients/sponsors identification,
names of Investigational Medicinal Product (IMP) or clinical trials acronyms could
not be used.
5.2.2. Training
Every new collaborator that joins Eurotrials must follow a Training Program
related with the role that will perform in the company.
Such trainings may be categorized as:
 Job Specific
This training requires the reading and understanding of Eurotrials Quality Manual,
Integration Manual, SOPs and additional reference documents (e.g. ICH-GCP,
European directives, local legislation, among others) relevant to the job
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description/function of the CRA as per the Company Training Matrix. In what
concerns the company SOPs, some SOPs are mandatory to all collaborators but
others are specific to each job description.
In addition to the job initial training that every new collaborator performs, there is
an Annual Training Plan, which aims to assure staff continuous training and
quality of the activities developed. There is a constant assessment of training
needs within Eurotrials so the Company Annual Training Plan include as much as
possible such training needs. This plan may be updated with new identified
training needs whenever justified.
 Project Specific
For each study it is essential to have Project Specific Training. Such training
covers at least the following topics: Therapeutic area, Protocol, Monitoring
Manual, Communication Plan, CRF, Informed Consent, study procedures, project
applicable SOPs and related forms, either from Sponsor or CRO.
Upon Sponsor agreement, the responsible CRA always made a brief introduction
to the CRA trainee before starting any study activities.
During this 9-month period there was the opportunity to have training in several
studies from different Sponsors. In addition to the topics highlighted above, there
was also the opportunity to perform additional project specific trainings like in
InForm® and Oracle® Software’ e-CRFs and in a Clinical Trial Management
System (CTMS) named IMPACT MySites, that supports online and offline
monitoring activities and the collection of associated data during site visits(16) by
CRAs.
5.2.3. Characterization of the Clinical Trials
Until the 31 of May of 2011, the CRA trainee performed activities within18
different clinical trials as per Tables 3 and 4 bellow.
Information regarding projects in which the training was focused is described in
Appendix B.
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Table 3 –Characterization of the Clinical Trials where CRA trainee was involved.
CT Ref.
No. Therapeutic Area Phase Randomized? Blind Comparator?
1 Dermatology IIIb/IV Yes Open Label Yes
2 Pneumology III Yes Double Blind Yes
3 Ophthalmology IIIb Yes Single Blind Yes
4 Cardiology IV Yes Double Blind No
5 Proctology II Yes Single Blind No
6 Cardiology II Yes Double Blind No
7 Infectious Diseases III Yes Double Blind Yes
8 Nephrology III Yes Open Label Yes
9 Ophthalmology IV Yes Double Blind Yes
10 Oncology II Yes Open Label Yes
11 Oncology III Yes Double Blind No
12 Oncology II Yes Open Label Yes
13 Ophthalmology IV No Open Label No
14 Cardiology III Yes Double Blind Yes
15 Allergology II Yes Double Blind No
16 Neurology III Yes Double Blind No
17 Rheumatology III Yes Double Blind No
18 Neurology III Yes Double Blind Yes
Table 4 – Details of Global Distribution of Clinical Trials where CRA trainee was involved.
CT Ref. No. Type of Client International Study? Multicentre?
1 Multinational CRO Yes Yes
2 Multinational CRO Yes Yes
3 Multinational CRO Yes Yes
4 Multinational CRO Yes Yes
5 Local Sponsor No Yes
6 Local Sponsor No Yes
7 Multinational CRO Yes Yes
8 International Sponsor Yes Yes
9 International Sponsor No Yes
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10 Multinational CRO Yes Yes
11 Multinational CRO Yes Yes
12 Multinational CRO Yes Yes
13 International Sponsor Yes Yes
14 Multinational CRO Yes Yes
15 Multinational CRO Yes Yes
16 Multinational CRO Yes Yes
17 Multinational CRO Yes Yes
18 Multinational CRO Yes Yes
Of these 18 trials, the majority are international, multicentre, randomized, double
blind trials, as observed in Tables 3 and 4. It is also possible to verify that the
CRA trainee worked with several types of sponsors/clients, which enriched her
experience and capacity of adaptation to the different SOPs, communication and
working methodologies. Of the 18 CTs, only 3 were conducted locally and of
these, only one belongs to an International Sponsor.
In what concerns to clinical trials phases, of the 18 studies that were
characterized per phase, 5 were phase II, 9 were phase III, 1 was phase III/IV
and 3 were phase IV. In comparison to data from Eurotrials, it is possible to
observe that in both cases, phase III clinical trials represent the largest
percentage. Nevertheless, according to Figure 11, no studies were performed in
phase I, and phase IV studies were less common than phase II.
Figure 11 - Distribution of Clinical Trials where CRA trainee was involved according to study
phase.
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The activities developed within each study were different according to the clinical
trial stage (feasibility, qualification, initiation, monitoring and end of study), study
protocol, sponsor and study sites.
Figure 12 outlines an overview of the stages of the Clinical trial life cycle, from
Project Initiation approval (Sponsor) until the development of the Clinical Study
Report (CSR) and CSR submission to Competent Authorities (Project
Conclusion).
Figure 12 - Clinical Trials Life Cycle.
During the 9-month period, many different activities from the overview mentioned
in Fig.12 were performed as CRA Trainee. In Figure 13, it is possible to observe
that Qualification was the only stage not covered during the training since the
projects where the CRA was involved were not in this specific phase of the
process.
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Figure 13 - Overview of developed activities within Clinical Trials Life Cycle.
In Appendix C it is also possible to have an overview of the training activities
developed per month within the several Clinical Trials.
The following sections describe the important steps in clinical trials monitoring
along with the CRA trainee experienced activities by the.
5.2.4. Archive and Documentation Management
“Documentation of research activities must be securely retained to provide
evidence of activities”(17), for example, in case of a regulatory inspection or a
sponsor representative audit.
In a clinical trial, there are three major documentation archives: Investigator File
(IF), Pharmacy File (PhF) and Trial Master File (TMF). The IF and PhF are kept
in the investigational where study is performed and in the related pharmacy,
respectively. Such Files include study and site specific documents. PhF is part of
IF and must include mainly, information on investigational product and related
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records. The TMF contain all study essential documentation as well as specific
documents from all investigational sites and other relevant documents, when
applicable.
Every clinical trial should have a TMF Maintenance Plan or similar document
where all procedures to be performed regarding study file management must be
described. It must include information about who is responsible for keeping the
files, where TMF physical archive is located, if there is local and/or central files,
the frequency of documents shipment to the central file and which procedures
should be followed, if applicable, among others.
In some of the 18 clinical trials, original documents were sent frequently to a
central TMF while, for others, TMFs were kept locally until the study termination.
Independently of the TMFs locations (central or local) it was essential to
continually update the TMF and keep a checklist with all documents archived.
The CRA trainee was able to verify that such checklist tool was essential for
ensuring that all documentation was traceable and also for supporting in the
identification of documents to be obtained from the investigational sites.
Based on the different clinical trials “age”, different approaches on filing were
able to be followed. In some cases TMF was strictly paper, located in Eurotrials
under effective CRA control, while for the most recent ones, all documents are
archived electronically. This later cases were more challenging since the effective
TMF was located in a different region of the world only accessible through portals
or other internet tools, less controllable by the CRA and more dependent on other
project teams work.
5.2.5. Feasibility
This process relates the stage where the sponsor or designee launches a
Feasibility Study Assessment (FSA) in order to select the best sites/countries to
participate in a clinical trial.
Considering that Eurotrials is a CRO, in general the first contact regarding this
FSA comes from CRO or Sponsor directly. This request may include minimum
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information on the study protocol, indication, IP and main inclusion/ exclusion
criteria and the feasibility questionnaire (FQ). Although sometimes the sponsor
gives names and contacts of potential investigators, it can also be requested to
the CRO to refer some names.
The next step is to contact potential investigators, via e-mail or telephone, in
order to introduce the study and ask for their interest in receiving more
information and answering the feasibility questionnaire. In cases where the
potential investigators are interested, a Confidentiality Disclosure Agreement is
signed between both parts (if required by Sponsor). Feasibility questionnaire and
protocol or protocol summary, as applicable, is then sent to sites. CRA must be
able to support investigators with any question about the questionnaire and must
follow-up with sites so that they answer the FQ within predefined timelines.
After FQs are completed and returned, Sponsor evaluates them and on the basis
of the answers given pre-selects the most suitable sites for that specific clinical
trial. It may be necessary to request for additional sites answers if sponsor
cannot decide only based on the information collected in the first FQ and some
additional questions are performed.
The CRA trainee participated in 5 clinical trials that were infeasibility stage. It was
a very interesting and challenging step of the training due to several reasons:
 The difficulty to contact the potential investigators
 Make them answer the questionnaires that can sometimes be very
exhaustive, in very tight timelines
 Make them deliver the necessary documents (CDAs and FQs)
The CRA Trainee verified that although the timeline is usually reasonable, in
practice, it becomes really stressful to get all needed FQs answered on time.
Investigators are very busy and the support provided by the CRA can only be
over the phone since at this stage the CRA usually does not have sponsor
approval to go to the sites. Nevertheless it is important to highlight that the
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scientific interest of the information that is provided during this stage is directly
linked with the initial Investigator interest and the FQ response rate from sites.
It was also realised that this Feasibility stage may represent the chance of
additional studies coming to Portugal and consequently have further projects
services contracted to Eurotrials.
Once sponsor selects the sites/countries according to FQs results, the project
usually moves to the next stage, the Qualification of the sites.
5.2.6. Qualification
Qualification is one more step in the process of selecting investigators and
clinical sites to conduct the trial. This step is not always performed due to
previous experience with a site/investigator or due to allocation of this
responsibility to other company (or even the sponsor). The objective of this
process is to select investigators who have the experience, interest in
participating in the study, and are able to execute the trial as planned. The
potential investigator should be able to recruit patients within the projected time
period for subject enrolment, and should have a qualified research team and
adequate clinical research facilities to carry out the research”(18).
The qualification phase usually requires a visit to the investigational site to verify
the information transmitted by investigator on the feasibility questionnaire. This is
a very important visit for ensuring appropriate site selection and for the future
study conduction.
Unfortunately, it was not possible for the CRA trainee to prepare or participate in
a qualification visit. Nevertheless, it is expected to perform this type of visits
during next months, as there are some trials in which feasibility phase is ending.
5.2.7. Clinical Trials Application to National Authorities
In Eurotrials, there is a specific group, the CT Start-up Team that is responsible
for the process of application of documents to INFARMED - the Competent
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Authority (CA), CEIC - Central Ethics Committee (Central EC) and CNPD - the
National Data Protection Authority.
In Portugal, the initial application of a CT must be submitted to INFARMED, CEIC
and CNPD. The CT application to these authorities should be performed in
parallel and their approval timelines are summarized in Figure 14.
Figure 14 – Approval timelines of a Clinical Trial Application.
CEIC and INFARMED Application
There are no deadlines defined for the initial CT application to the Central EC.
The EC meeting dates are always on the first Friday of each month. Considering
the 60 days for review of a new Clinical Trial Application and the validation period
(10 days maximum) – it is possible to estimate when the CT Approval will be
expected. The CRA trainee realised that this information is crucial for the
remaining planning of the clinical trials activities. In many cases this forecasted
date is requested by Sponsor or CRO project team prior to the effective CT
application is performed.
Following the Submission to Central EC, the internal EC process is:
1. Validation by the Central EC (clock starts counting 60 days)
2. Possible Questions by the Reviewer (clock stops until questions are
answered, and after this, it starts again)
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3. Reviewers send the Clinical Trial Submission to the next Plenary Session
(EC meeting dates provided above)
4. Conditional Approval is granted (This is a general study Approval and
being Conditional means that it will remain as so, until central EC receives
the signed Contracts with each site, after which they will send the final
Approval)
5. Notification of signed Contracts (can be for one site or several sites)
6. Final Approval is granted (per site or several sites, but will always be site-
specific Approval, which enables SIVs to be performed)
Portuguese central EC only issues the favorable opinions for initial submissions
and substantial amendments on their plenary meetings. This means that in case
of questions raised it is very important that the answers to those questions are
provided to Central EC until one week prior to their plenary meeting. Despite the
clock stops during that period, from CRO and Sponsor side the time never stops
and the CRA Trainee was able to verify that the Start-up Team must be able to
provide adequate clarifications (through amended ICFs, Declarations or other
remarks, as applicable) within the previewed deadlines, otherwise an additional
month may be needed for Central EC to assess the responses provided to their
clarifications and the correspondent approval in the next plenary session may be
obtained. Consequently that somehow simple step may have a significant impact
on the delay of the study initiation.
As ICF must be submitted to EC in the local language, the customization
(including translation process) of the Model ICF should start as early as possible.
Contract negotiations with study sites are generally performed in parallel with the
application process although some institutions require EC approval before
signing and even negotiating the contract. Nevertheless, at least a draft version
of contracts and a draft budget of study costs must be available for EC
submission.
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Regarding the CA, the approval process is similar to the described for Central EC
however the approval can be quickest due to their more frequent meetings.
EC questions usually focus on Informed Consent Form (ICF) wording, study
rationale and design while CA questions focus on the IMP.
The CRA trainee was involved in the application of a new clinical trial to CEIC
and INFARMED. From the several activities involved in this process, the CRA
trainee may refer specifically the support to the National Coordinator in the
elaboration of an Ethical Assessment Statement draft.
Overall, this CT application gave the CRA trainee the possibility of following and
becoming more familiar with study contracts and all other essential documents
needed for the CT application to Portuguese authorities.
CNPD Application
The National Data Protection Authority, do not have, by law, any established
timelines for the approval of a clinical Trial application. Yet, in general usually
this authority takes 3 months to approve the data collection within a specific
clinical trial.
In addition to initial and substantial amendments application to Central EC, CA
and CNPD, other notifications need to be performed to the several authorities
during the implementation and conduction of a clinical trial.
The CRA Trainee was able to be involved in some of those notifications, that
based on the flow of occurrence within a CT are mentioned in sections 5.2.11,
5.2.13 and 5.2.15 bellow.
5.2.8. Investigator Meetings
Investigator meetings (IMs) are an important opportunity for investigators
involved in a clinical trial to be trained in study protocol, meet other investigators,
share opinions and experiences, learning about potential problems before they
occur, ensure harmonisation of study procedures and clarify potential questions.
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Usually, investigators, other sites staff and project team members from sponsor
and/or CRO attend this kind of meetings.
Investigator meetings may include all global study sites or be organised on a
local basis. IMs can occur before clinical trial initiation and/or during the trial and
must address training in protocol, investigational product handling, safety
aspects, Laboratory and Interactive Voice Response System (IVRS), GCP
guidelines, and data recording. Pre-initiation IMs aim to prepare team sites in
trial-specific procedures, including data introduction in the CRF. IMs organized
during the clinical trial aim to give updated information regarding the study to
investigators and train new investigators in the trial(3).
During CRA training, the trainee was involved in the organization of 2 investigator
meetings and will have the opportunity to participate in one of them, a pre-
initiation IM of one of studies that is still in application. This IM, only for
Portuguese sites, will be presented by Sponsor and by the CRA trainee and will
be a challenging activity as it will be the first time the CRA trainee attends this
kind of meetings and as the responsible CRA for the trial.
5.2.9. CRA Training Meetings
CRA training meetings are events similar to Investigator Meetings but only CRAs
are present.
The CRA trainee will attend a CRA meeting in June 2011, in which she will be
trained in study protocol and procedures. This training will be crucial for the CRA
trainee as she will have to speak about some procedures in the previously
mentioned IM that will be occurring soon after that. This training will also be
essential for ensuring that appropriate training was made for the site initiation
visits (SIVs) that are expected to occur in September of this year.
Such meetings are considered as project specific trainings and need to be also
documented in the individual training records.
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5.2.10. Initiation
Study initiation is a critical step in a clinical trial and can only be performed after
all INFARMED, CEIC and CNPD requirements have been fulfilled as well as site
Administrative Board approval of the Clinical Study Agreement is obtained. The
following essential documentation must be obtained before the clinical trial
initiation visit may be performed:
 Authorizations from INFARMED, CEIC and CNPD
 Ethics Committee members list
 Curriculum vitae of all site members involved in the trial
 Local laboratory certification and its normal ranges (when applicable)
 Last approved versions of protocol and its amendments
 Confidentiality Agreement and signature page of protocol and
amendments signed by Principal Investigator
 Site/Investigator contract with Sponsor executed by all parties
 Site declaration regarding adequacy of facilities and human resources
 Any other additional required document according to the study, site and
sponsor.
On the Site Initiation Visit, the CRA must train the several site team members on
the protocol and study procedures, safety, IP handling and appropriate records to
be used, specific laboratory, nurse and imaging procedures and all additional
documents and forms related with the trial. This is a very demanding visit for the
CRA and is essential that the CRA is well prepared and has a deep knowledge of
the study, to be able to provide the right information during the training of the
different site team members. The training provided to the site staff during this visit
is very important for ensuring compliance with the protocol, GCP guidelines and
patients safety.
The CRA trainee had the opportunity to prepare and be present in an initiation
visit in one of the clinical trials – cardiology trial. It was possible to understand
how important is to prepare and to be capable to adapt the presentation of the
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initiation visit according to the site staff present in each moment of the SIV –
investigators, nurses, laboratory technicians and pharmacists.
5.2.11. Notification of inclusion of the first patient to Competent
Authorities
During the training experience, CRA trainee was asked to notify INFARMED and
CEIC about the inclusion of the first patient in a clinical trial for a site.
After study initiation, the first patient included in the study in Portugal must be
notified to CEIC and INFARMED. Moreover the first patient included in each
Portuguese site should also be notified. The first patient included in a site is
defined according to the date in which the first ICF in that site is signed by a
patient, regardless patient randomization or not.
5.2.12. Monitoring
Monitoring visits are an important step to evaluate site performance and the
focus of the CRA in patients’ safety and quality of data. CRA needs to:
 Evaluate the compliance to the protocol and the implementation of
protocol amendments
 Verify that patients Informed Consent was correctly obtained
 Evaluate medication compliance through drug accountability
 Verify the occurrence of adverse events and serious adverse events and
their notification according to local legislation timelines
 Perform source data verification (SDV), namely compare the information
recorded in CRF with the source documents like patient chart notes,
patients exam reports, nurse notes, etc.
 Evaluate temperature and humidity logs
 Update the Investigator File and Pharmacy File
 Collect essential documents from sites (example: Curriculum Vitae from
the study team)
 Train new study team members or re-train study members, if necessary
University of Aveiro | Autonomous Section of Health Sciences
Year 2010/2011
TrainingReport_IC_39215_05Jul2011.pdf Page 49 of 68
 Evaluate patient recruitment, including revision of exclusion and inclusion
criteria
 Verify if confidentiality of patients personal data is respected
 Confirm that only qualified/trained people work in the study and that they
were authorized by principal investigator (according to the authorization
log)
 Confirm that resources and equipment are still adequate and obtain
appropriate documentation, as applicable.
 Evaluate if pending issues from previous visits were solved and follow
them until resolution is available
 Discuss study status with Principal Investigator and applicable site team
members
Sometimes it is not possible to perform all the above activities in the same
monitoring visit due to the number of pending issues from previous monitoring
visits, number of subjects, SDV backlog and availability of study team.
If appropriate the CRA must re-schedule another monitoring visit with the site in
order to be able to review all the pending items and verify the overall site
performance.
All these activities performed by the CRA must be in accordance with the Study
Monitoring Plan. This plan defines all monitoring requirements, frequency and
standards applicable to the specific clinical trial.
During the training period the CRA trainee had the opportunity to be present in
some monitoring visits that were performed with the CRA supervisors that were
also the responsible CRAs for the different studies. Within the several sites
visited the CRA Trainee was able to verify that some sites were more organized
and had more availability and human resources than others. In these monitoring
visits the CRA trainee performed the following activities:
 Investigator File and Pharmacy File review and update
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 Queries and pending issues resolution
 Verification of the occurrence of any protocol deviation
 Drug accountability
 Preparation of medication shipment to return to Sponsor for destruction
 Verification of new AEs existence
 Verification of data loggers (temperature and humidity logs)
 Source Data Verification
 Collection of some documents from sites
 Confirmation if the new ICF version was signed by patients
 Status with site teams in order to get feedback about possible difficulties,
forms unavailable at sites and any other issues
In addition to the site monitoring visits, a great variety of other in-house
monitoring activities were also performed:
 Contact with sites and Sponsor (including status updates)
 Quality Control checks, archiving documents and sending them to central
file
 Prepare monitoring visits
 Prepare monitoring visit reports
 Write and send confirmation and follow-up letters
 Prepare and participate in a Sponsor audit
 Develop a clinical trial file checklist
 Prepare Investigator and Pharmacy Files
 Remote Monitoring of e-CRF and follow-up queries
 Supporting in investigator meetings preparation
 Collection of essential documents from sites
 Evaluate site recruitment and propose recruitment enhancement actions
 Prepare payments to sites
 Support the activities for the development of a Clinical Study Report
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In future, it is expected to perform further monitoring visits more autonomously
and considering also the recent involvement in some projects that are in the
monitoring phase.
5.2.13. Elaboration of a Progress Report
Progress Reports should be submitted annually, or more frequently, to Central
EC. This document is normally written by investigators and is a summary of the
clinical trial status(19). The CRA trainee supported the responsible CRA in the
development of such document for one clinical trial - in cardiology. This Progress
report will be reviewed and signed by study National Coordinator before
notification to Sponsor and Authorities.
This report included topics like, present study status, CT application and approval
timelines, number of patients included, completed and discontinued, SAEs as
well as any protocol deviations and actions implemented by the sites.
This document is very important to provide more frequent overview of the study
conduct and compliance of the several sites to the authorities, especially in
longer trials, like the oncology ones.
5.2.14. Close-out/Termination
The close-out visit to a site usually takes place after Database lock, although it
can be performed before its definitive closure upon Sponsor and Principal
Investigator agreement. It is the last CRA visit regarding the study to the sites
and should be performed only when all data queries related to site are resolved.
It is important to notify local authorities about study termination and archive the
respective documentation and correspondence.
The ideal situation would be to schedule the visit with all team members of the
site to finalize pending issues and to inquire them about their opinion on site
performance and overall satisfaction with the study(20).
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In a clinical trial, the close-out visits’ objective is to ensure that:
 All queries are resolved
 All adverse events are documented and reported appropriately
 All randomization codes have been returned from blinded sites without
being opened (excepted in reported emergency situations), if applicable
 Drug accountability is complete and accurate or any deviations
documented
 All study medication was reconciled and returned
 Shipment receipts are completed and accurate
 The regulatory binder is updated
 Specific documentation from site is up-to-date (e.g.. CVs, Laboratory
normal ranges, Authorized Log and Monitoring Visit Log)
 The correct archive and maintenance of study files (a form must be signed
by Principal Investigator to document his responsibility in the long term
retention of files and the IF availability in case of Inspection)
“The correct archive and maintenance of study files” is an important issue in this
stage. In some cases, an external company may be contracted to archive study
files if the site is unavailable to keep them. According to ICH guideline E6,
“essential documents should be retained until at least 2 years after the last
approval of a marketing application in an ICH region and until there are no
pending or contemplated marketing applications in an ICH region or at least 2
years have elapsed since the formal discontinuation of clinical development of
the investigational product”(19). Although, according to the Portuguese Decree-law
no. 102/2007 of April 2 (20th Article), clinical trial essential documents must be
retained for at least 5 years, typically, wherever files location, all study
documents are usually kept archived for at least 15 years(3, 21).
One of the clinical trials in which activities were developed, was in termination
phase and it was necessary to schedule, prepare and conduct the study close-
out visits.
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The major lesson learned was the importance of constantly updating site files,
keeping a written registration on which documents were left at the site and which
were collected and to have an updated list of all pending issues.
The CRA Trainee was able to verify that a complete and effective close-out visit
of a clinical trial site is a good indicator of the quality of the monitoring activities
throughout the study and of the site team commitment during the clinical trial.
5.2.15. Development of a Clinical Study Report
One of the most important documents in a clinical trial is the Clinical Study
Report (CSR). The CSR is the document, after global completion or termination
of a trial, where results and its interpretation are registered and conclusions,
regarding the study design, statistical analyses performed, objectives
accomplished, among other issues, are discussed.
The Clinical Study Report of a clinical trial (or summary of the CSR) must be
notified within 1 year after the trial global conclusion to the authorities,
INFARMED and CEIC.
The trainee developed a first draft of an abbreviated CSR, under supervision and
guidance of the Eurotrials Medical Writer (MW) according to Sponsor requests,
guideline ICH E3[19] (Structure and Content of Clinical Study Reports) and FDA
Guidance for Industry[20] (Submission of Abbreviated Reports and Synopses in
Support of Marketing Applications). Since the CRA trainee was not involved in
the project from start, the major difficulties found were to understand the project
and to identify which information should be included in the report. On the other
hand, it was excellent to understand how data collected from patients in CRFs is
transformed in “clean data” and finally in conclusions that have impact in data
submitted to authorities for new Investigational products or new indications
approvals.
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5.2.16. Project Hand-over
Despite the training period did not contemplate this specific topic, the CRA
trainee considered this to be also a relevant item within the CRA activities.
The Project hand-over is the transition of a project and all its relevant issues, like:
essential documentation, status of sites and available reports, pending issues,
contacts of team members, patient status, location of documents, applicable
SOPs, Forms and regulations, communication plan among others, in any time of
its lifecycle, from current person/team to a new CRA/team. The main objective of
this process is to ensure that a new resource approved by Sponsor or designee
and adequately trained in the project will ensure the project continuation, so no
gaps in information or procedures may occur during the handover. The CRA
trainee experienced a project hand-over. The previous CRA stopped her
participation in the study due to personal reasons and it was given the
opportunity to the CRA trainee to become the responsible CRA for that study.
The CRA Trainee was able to understand that the transition of the study is a
sensitive issue that demand a significant amount of time to be dedicated to this
activity. Per personal experience it was understood that as much as possible
both the current and the new CRA should perform a monitoring visit to each of
the sites together so that applicable study site issues may be discussed and
transitioned on site and appropriate site team introduced to the new CRA.
5.2.17. Audits
An audit is a “systematic and independent examination of trial related activities
and documents to determine whether the evaluated trial related activities were
conducted, and the data were recorded, analysed and accurately reported
according to the protocol, sponsor's standard operating procedures (SOPs),
Good Clinical Practice (GCP), and the applicable regulatory requirement(s)”(19).
There are two types of audits: internal and external. Internal audits are performed
within the company quality management system implementation and are
important to assure the quality of the studies activities and of the overall
processes performed by the company staff.
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External audits are audits performed by the Sponsor or delegated auditors to the
clinical trials or other activities implemented by Eurotrials or to Eurotrials Quality
Management System, typically designated as system audits.
During the training period a Sponsor audit was performed to the study file of one
of the studies in which the CRA Trainee was working on. This audit was a great
opportunity to understand how important is to have a good file tracking and to
learn how to prepare an audit. It also demonstrated how to improve job
performance in future cases and it was an excellent chance to have a better idea
of Sponsor way of working, values, culture and objectives.
Since Eurotrials is an ISO 9001:2008 certified company, during the training
period the CRA Trainee was also able to participate in the preparation and follow-
up of an ISO surveillance audit. The focus of this type of audits is different from a
Sponsor audit since the ISO auditor wishes to ensure that the ISO Standards are
followed overall and that globally the Company continues to develop its activities
towards quality improvement.
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6. DISCUSSION AND CONCLUSION
The 9-month experience as a Clinical Research Associate in Eurotrials was
fantastic. For this opinion contributed not only the understanding of the CRA job
itself but also a good work environment that is due to an excellent interaction
between all collaborators at Eurotrials.
Clinical Trials department of Eurotrials is a great place to learn. All opportunities
are given to all collaborators, including the trainees. Everyone is available to
support and explain, and the interaction between all departments allows
understanding the real flow of information that would not be possible if, for
example, Regulatory Affairs Department, Data Management and Biostatistics did
not exist.
The transdisciplinar experience within Data Management and Biostatistics
Departments were important to realise, what are their responsibilities, how
important their activities are and their influence in the job of the CRA. However,
the trainee would like to have this kind of opportunity in other Eurotrials
departments, for e.g., Pharmacovigilance and Quality, and it would be excellent if
the duration of these interactions could be extended. It would be a good way to
know Eurotrials collaborators’ work and identify new interests and other
professional development areas.
In what concerns the monodisciplinar experience, it was really positive and
confirmed how interesting and challenging this job is. All knowledge acquired
during the Degree in Biomedical Sciences and during the Master in
Pharmaceutical Biomedicine were reviewed and many topics became clearer. It
is recognised that the structure and curricular units of this master were essential
to have a better understand of real-life activities developed within a Research
Project. There is still knowledge to be acquired and updated, as this is an area in
constant changing.
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However, the trainee had the opportunity to be involved in 18 studies, in different
therapeutical areas, stages, procedures and client culture. This experience,
although intense, increased the range of skills acquired in a short notice period
(9months).
The most important outcome of this training was the increased interest for this
area and the improvement observed during this period. During the training period
the CRA trainee was invited by Eurotrials to assume the role of CRA and was
assigned with on-going clinical trials with specific responsibility and accountability
for the trials activities.
In the near future, this will allow to gain experience in many other activities that
are usually under CRA responsibility and that were not possible to develop during
the training. Mainly to perform additional sites visits as well as to become more
autonomous. The clinical trials presently assigned and the perspective of
assignment/involvement in future trials are very promising and challenging,
aspects that are essential for personal motivation and career progression. This
way, there will be the opportunity to acquire more knowledge and experience as
a CRA and also to grow as a person.
Even considering that this was the first internship experience between Eurotrials
and University of Aveiro, it may be important to consider, for future trainings, to
have an initial well-structured plan with training objectives in order to keep a
better track of the activities experienced. For example, the plan should be
discussed between Eurotrials and University of Aveiro in order to have a better
understanding of what activities would be important to develop and assure that
initial training objectives are accomplished.
Despite being included within the company daily work and being considered a
regular collaborator, the CRA trainee also considered that the Project Manager
delegated for the supervision and coaching of the trainee could have a better
performance in this activity if the above-mentioned plan was available.
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Still, the greatest difficulty observed during the training was the capacity to
reconcile the training with Master units study and evaluations and also the report
development. It was also very challenging the need to improve communication
skills and learn how to work in a team, in a daily-basis.
In a lifelong learning basis, the CRA trainee will continuously try to improve her
personal and professional skills taking into account the already acquired
background impossible to achieve without the support of University of Aveiro and
Eurotrials.
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8. APPENDICES
8.1.APPENDIX A
Glossary(19, 24, 25)
Adverse Event (AE) - Any untoward medical occurrence in a patient or clinical
investigation subject administered a pharmaceutical product and which does not
necessarily have a causal relationship with this treatment. An adverse event (AE)
can therefore be any unfavourable and unintended sign (including an abnormal
laboratory finding), symptom, or disease temporally associated with the use of a
medicinal (investigational) product, whether or not related to the medicinal
(investigational) product.
Audit - A systematic and independent examination of trial related activities and
documents to determine whether the evaluated trial related activities were
conducted, and the data were recorded, analysed and accurately reported
according to the protocol, sponsor's standard operating procedures (SOPs), Good
Clinical Practice (GCP), and the applicable regulatory requirement(s).
Case Report Form (CRF) - A printed, optical, or electronic document designed to
record all of the protocol required information to be reported to the sponsor on each
trial subject.
Clinical Trial/Study - Any investigation in human subjects intended to discover or
verify the clinical, pharmacological and/or other pharmacodynamic effects of an
investigational product(s), and/or to identify any adverse reactions to an
investigational product(s), and/or to study absorption, distribution, metabolism, and
excretion of an investigational product(s) with the object of ascertaining its safety
and/or efficacy. The terms clinical trial and clinical study are synonymous.
Clinical Trial/Study Report - A written description of a trial/study of any
therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in
University of Aveiro | Autonomous Section of Health Sciences
Year 2010/2011
Page 61 of 68
which the clinical and statistical description, presentations, and analyses are fully
integrated into a single report.
Clinical Research Organization (CRO) - A person or an organization (commercial,
academic, or other) contracted by the sponsor to perform one or more of a
sponsor's trial-related duties and functions.
Electronic Case Report Form (e-CRF) - an electronic form that does the same
thing a paper CRF does. The clinical site types the data into an electronic form that
gets electronically submitted to the sponsor. Essentially, the sponsor is removing a
(paper-based) step and pushing the data entry from their internal (Data
Management) group to the clinical site.
National Coordinator - An investigator assigned the responsibility for the
coordination of investigators at different centres, in a country, participating in a
multicentre trial.
Good Clinical Practices (GCP) - A standard for the design, conduct, performance,
monitoring, auditing, recording, analyses, and reporting of clinical trials that provides
assurance that the data and reported results are credible and accurate, and that the
rights, integrity, and confidentiality of trial subjects are protected.
Informed Consent - A process by which a subject voluntarily confirms his or her
willingness to participate in a particular trial, after having been informed of all
aspects of the trial that are relevant to the subject's decision to participate. Informed
consent is documented by means of a written, signed and dated informed consent
form.
International Conference on Harmonization (ICH) - International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use is a joint initiative involving both regulators and research-based industry
focusing on the technical requirements for medicinal products containing new drugs.
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Investigational Product - A pharmaceutical form of an active ingredient or placebo
being tested or used as a reference in a clinical trial, including a product with a
marketing authorization when used or assembled (formulated or packaged) in a way
different from the approved form, or when used for an unapproved indication, or
when used to gain further information about an approved use.
Inspection - The act by a regulatory authority(ies) of conducting an official review of
documents, facilities, records, and any other resources that are deemed by the
authority(ies) to be related to the clinical trial and that may be located at the site of
the trial, at the Sponsor's and/or Clinical Research Organizations (CROs) facilities
or at other establishments deemed appropriate by the regulatory authority(ies).
Investigator - A person responsible for the conduct of the clinical trial at a trial site.
If a trial is conducted by a team of individuals at a trial site, the investigator is the
responsible leader of the team and may be called the principal investigator.
Monitoring - The act of overseeing the progress of a clinical trial, and of ensuring
that it is conducted, recorded, and reported in accordance with the protocol,
Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the
applicable regulatory requirement(s).
Protocol - A document that describes the objective(s), design, methodology,
statistical considerations, and organization of a trial. The protocol usually also gives
the background and rationale for the trial, but these could be provided in other
protocol referenced documents.
Protocol Amendment - A written description of a change(s) to or formal
clarification of a protocol.
Sponsor - An individual, company, institution, or organization which takes
responsibility for the initiation, management, and/or financing of a clinical trial.
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Standard Operating Procedures (SOPs) - Detailed, written instructions to achieve
uniformity of the performance of a specific function.
Statistical Analysis Plan (SAP) - A document that contains a more technical and
detailed elaboration of the principal features of the analysis described in the
protocol, and includes detailed procedures for executing the statistical analysis of
the primary and secondary variables and other data.
Trial Site - The location(s) where trial-related activities are actually conducted.
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8.2.APPENDIX B
Clinical Trials Experience
Clinical Trials Monitoring activities:
1. May 2011/ongoing – Dermatology – CRA trainee in a multicentre, open label,
randomized, Phase IIIb/IV exploratory clinical trial in patients with moderate to
severe plaque psoriasis.
2. April 2011/ongoing – Pneumo-Oncology – Multicentre, randomised, double-
blind, Phase III trial to investigate the efficacy and safety of therapy in patients
with stage IIIB/IV or recurrent non-small cell lung cancer after failure of first line
chemotherapy – Development of activities as CMA trainee (Clinical Monitoring
Associate) of the study.
3. April 2011/ongoing – Ophthalmology – In-house CRA Support activities in a 2
year randomized, single-masked, multicentre, controlled phase IIIb trial in
patients with macular edema and visual impairment secondary to Diabetes
Mellitus.
4. February 2011/ongoing – Cardiology – Multicentre, double-blind, randomized,
placebo-controlled, parallel group, prospective, event driven phase IV study on
Pulmonary Arterial Hypertension. Co-monitoring activities related with study
documentation, namely preparation of Central File documentation and
correspondent Quality Checks.
5. September 2010/ongoing – Proctology – In-house CRA co-monitoring
activities on a phase II, multicentre, randomized, single-blind, placebo-controlled
study in patients with chronic anal fissure, namely audit preparation, Trial Master
File revision, support in close-out visits preparation and sponsor
communications.
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6. September 2010/ongoing – Cardiology – co-monitoring activities in a
exploratory, phase II, randomized, double-blind, parallel group, placebo-
controlled study in patients with Diabetes Mellitus type 2 and Dyslipidaemia,
treated with statins, namely in Investigator Site Files preparation, support to Site
Initiation Visit.
7. February 2011/April 2011 – HIV – Co-monitoring activities in a phase III,
multicentre, randomized, double-blind, double-dummy study in patients infected
with HIV-1.
8. February 2011/March 2011 – Nephrology – In-house CRA Support activities in
a Prospective, randomized, multicentre, open label phase III study to evaluate the
efficacy and safety of Immunosuppression following a heart-beating cadaveric
renal transplantation.
9. February 2011 – Ophthalmology – Design of a Clinical study report of a phase
IV, multicentre, randomized, double-blind, active-controlled study in patients with
open-angle glaucoma or ocular hypertension.
10.November 2010/March 2011 – Oncology – In-house CRA Support activities in
a phase II, open-label, multicentre, randomized, positive-controlled study in
patients with Metastatic Colorectal Cancer, namely on Essential Documentation
revision and final Country File documents reconciliation.
11.October 2010/January 2011 – Oncology – Support to CRA in a phase III,
multicentre, randomized, double-blind, placebo-controlled study in patients with
Metastatic Gastric Adenocarcinoma, namely sites’ start-up activities, related
sites communication and Sponsor regular status updates.
12.October 2010/December 2010 – Oncology – Support to CRA in a phase II,
open-label, multicentre, parallel group, randomized study in patients with Breast
Cancer, namely in Trial Master File reconciliation for close-out activities.
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13.September 2010 – Ophthalmology – CRA support activities on a prospective
pilot study in patients with cataracts, namely in site Initiation Visit documentation
preparation.
Feasibility Studies Activities:
14.May 2011/ongoing – Cardiology – feasibility activities on a phase III,
multicentre, randomized, double-blind, parallel-group study in Patients with Type
2 Diabetes Mellitus with Inadequate Glycaemic Control.
15.April 2011/ongoing – Allergology – feasibility activities on a phase II,
multicentre, randomized, double-blind study, with subcutaneous immunotherapy
at different doses in parallel-groups and placebo-controlled, in patients with
Rhinoconjuntivitis ± Asthma sensitized to Phleum Pratense.
16.April 2011/ongoing – Neurology – feasibility activities on a multicentre, phase
III randomized, double-blind, 3-Arm, placebo-controlled, 78-week parallel group
study to assess the efficacy and safety of the therapy in subjects with Mild to
Moderate Alzheimer’s Disease.
17.January 2011/ongoing – Rheumatoid Arthritis – feasibility activities on a
phase III, multicentre, randomized, double-blind, placebo-controlled study in
patients with active Rheumatoid Arthritis.
18.October 2010/December 2010 – Neurology – Co-monitoring activities on a
phase III, multicentre, randomized, double-blind, double-dummy, positive-
controlled study in patients with Epilepsy, namely sites contacts and follow-up
until feasibility questionnaire was obtained.
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8.3.APPENDIX C
Developed Activities during the Training
Training Plan - Eurotrials Clinical Trials Department
Study Activities 2010 2011Sep Out Nov Dec Jan Feb Mar Apr Mai
Study Specific Documents Familiarization
Protocol X X X X X X X
Informed Consent Form X
Case Report Form X X X X
ICH/Legislation/SOPs X X X X X
Feasibility
Feasibility Contacts X X X X X X X X X
Feasibility Visits
Feasibility Status to Sponsor X X X X X X X X
Study Implementation
Pre-study Visits (Preparation, execution and
report)
Site Contracts preparation X X
Submission to CNPD
Submission to CEIC X X
Submission to INFARMED X X
Study Monitoring
Investigator and Pharmacy Files X X
Trial Master File X X X
Initiation Visit (Preparation, execution and
report) X
Monitoring Visit (Preparation, execution and
report) X X
Safety Information Notification (AEs/ ASR)
Newsletters X
Progress Reports (INFARMED) X
In-house Monitoring (communication with
Sponsor and sites, status reports, CRF
revision and, management of queries, drug,
supplies and documents)
X X X X X X X X
Study documents translation X
Investigator Meeting Preparation X X
In-house Monitoring (Laboratory) X X X X X X X X
Drug accountability X X
Study Payments to sites X X
Audit (Preparation, execution and follow-up) X X X X
Study Close-out/Termination
Investigator and Pharmacy File X X
Trial Master File X X
Close-out Visit (Preparation, execution and
report) X X
Data Management and Database Close-out
Statistical Analysis
CSR (Clinical Study Report) X
